



HLT08 INFECT-MET

B) Questionnaire for clinical laboratories and facilities on									
Nucleic acid tests (NAT) for diagnostics of patients with infectious diseases									
1 Number of all analyses (including non-NATs) for diagnostics of infectious diseases									
□ < 100 / month	🔲 100 - 1000 / month	□ > 1000 / month							
2 Percentage of NATs used fo	r diagnostics of infectious d	iseases							
□ < 10%	□ < 25%	□ < 50%							
□ < 75%	□ > 75%								
3 Target bacteria / viruses / otl	her infectious agents								
M. tuberculosis	☐ MRSA	□ SARS							
cytomegalovirus (CMV)	adenovirus	🔲 influenza A/B							
	Epstein-Barr Virus (EBV)	HBV / HCV							
other pathogens, i.e.									
4 Are rapid NATs used in your	laboratory?								
☐ yes	🔲 no								
5 Mainly used workflow for ha	ndling / sample preparation a	and NA amplification							
manual preparation (DNA ext	traction, purification, etc.) requi	ired before amplification							
complete tests, automated preparation and workflow in one / different instruments									
complete tests, all reagents in	ncluded in cartridge								
6 Type of sample									
🔲 blood / plasma	☐ swab	bioptic tissue							
other samples, i.e.									
7 Please indicate on which me	thod the majority of NATs is	based?							
temperature cycling PCR	isothermal amplification techniques								
branched DNA									
8 Typical turnaround time for the mainly used workflow Sample preparation to result) ?									
□ < 15 min	□ < 30 min	🔲 < 1 h							
□ < 2 h	□ > 2 h								



INSTAND e.V.

Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e.V.





HLT08 INFECT-MET

9 For which target NATs?	bacteria / vir	uses or ot	her path	nogens	is an ur	gent ne	ed for rapid	
target organism	estimated incidence of tests							
e.g. MRSA	🔲 < 10 / month		🔲 10 - 50 / month			□ > 50 / month		
	🔲 < 10 / month		🔲 10 - 50 / month			🗌 > 50 / month		
	🔲 < 10 / month		🔲 10 - 50 / month			□ > 50 / month		
	🔲 < 10 / month		🔲 10 - 50 / month			□ > 50 / month		
10 Are qualitative N	NATs sufficie	ent or quar	ntitative	NATs r	equired	?		
qualitative test su	ufficient	-	🗌 quan	titative t	est requ	ired		
dependent on tar	rget organism							
11 Requested turna	around time	for rapid N	IATs					
e.g. MRSA	🔲 < 2 min	□ < 5	min	□ < 1	0 min	□ < 1	5 min	
	🗌 < 2 min	□ < 5	min		0 min	🔲 < 15 min		
	🗌 < 2 min	□ < 5	min	□ < 10	0 min	□ < 1	5 min	
	🗌 < 2 min	□ < 5	min	□ < 1	0 min	□ < 1	5 min	
12 Requested dete	ction limit or	analytical	sensiti	vity (in	pure tes	st samp	les)	
target organism e.g. MRSA	□ < 10	DNA / R □ < 50		v numbe : 100	er / mL □ < 20	00	□ < 500	
	□ < 10	□ < 50	□ <	100	□ < 20	00	□ < 500	
	 □ < 10		<	: 100		00	 □ < 500	
	 < 10	<u> </u>	_	: 100	< 20		<u> </u>	
13 Reasonable cos	t per NAT							
e.g. MRSA	□ < 0.5 €	□ < 1€	1 🗌	€-2€	2€ ·	- 4€	□ 4€ - 6€	
	□ < 0.5 €	<u> </u>	1 🗌	€-2€	2€ ·	- 4€	□ 4€ - 6€	
	□ < 0.5 €	<u> </u>	1 🗌	€-2€	<u></u> 2€·	- 4€	□ 4€ - 6€	
	□ < 0.5 €	<u> </u>	□ 1	€-2€	2€ ·	- 4€	□ 4€ - 6€	
14 Do you intend to	o purchase e	quipment	for rapi	d NATs	?			
🔲 no	🗌 next y	ear	🗌 n	ext thre	e years		ater	
15 Laboratory / ins laboratory name mainly used instrum								
mainly used test kit								
date								



INSTAND e.V.

Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e.V.